Comparison of effectiveness and safety between baricitinib and tocilizumab in severe COVID-19: a retrospective study
Our study suggests survival and safety are significantly better for baricitinib compared to tocilizumab in severe COVID-19. Clinical randomized trials are needed for confirmation.
Authors
- Ioannis Grigoropoulos
- Antonia Digalaki
- Chrysavgi Kosti (ORCID: https://orcid.org/0009-0008-7170-2890)
- Katerina Dimakou (ORCID: https://orcid.org/0000-0001-7457-4611)
- Anastasia Antoniadou (ORCID: https://orcid.org/0000-0003-0991-9198)
- Κonstantinos Thomas (ORCID: https://orcid.org/0000-0002-7489-7776)
- Dimitra Kavatha
- Ioannis P. Tomos (ORCID: https://orcid.org/0000-0002-9978-4823)
- Serafeim Chrysikos (ORCID: https://orcid.org/0000-0002-2945-8205)
- Georgios Hillas
- Pinelopi Kazakou
Institutions
- National and Kapodistrian University of Athens (GR)
- Chest Diseases Hospital (KW)
- Sotiria General Hospital (GR)
Publication Details
- Journal
- Expert Review of Respiratory Medicine
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1080/17476348.2025.2473486
- Citations
- 1
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.40